Prof Anzala Aggrey O Publications
PDF version
  1. Periodic Presumptive Treatment for Vaginal Infections May Reduce the Incidence of Sexually Transmitted Bacterial Infections
  2. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial
  3. Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort
  4. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
  5. CD4:CD8 lymphocyte ratio as a quantitative measure of immunologic health in HIV-1 infection: findings from an African cohort with prospective data.
  6. Mucosal Blood Group Antigen Expression Profiles and HIV Infections: A Study among Female Sex Workers in Kenya.
  7. Cytokine and chemokine expression profiles in response to Mycobacterium tuberculosis stimulation are altered in HIV-infected compared to HIV-uninfected subjects with active tuberculosis.
  8. Canine distemper virus neutralization activity is low in human serum and it is sensitive to an amino acid substitution in the hemagglutinin protein.
  9. Creating an African HIV clinical research and prevention trials network: HIV prevalence, incidence and transmission.
  10. Randomized Trial of Periodic Presumptive Treatment With High-Dose Intravaginal Metronidazole and Miconazole to Prevent Vaginal Infections in HIV-negative Women.
  11. Acceptability and feasibility of repeated mucosal specimen collection in clinical trial participants in Kenya.
  12. Early HIV-1 infection is associated with reduced frequencies of cervical Th17 cells.
  13. Host genetics and viral load in primary HIV-1 infection: clear evidence for gene by sex interactions.
  14. Dynamics of viremia in primary HIV-1 infection in Africans: insights from analyses of host and viral correlates.
  15. Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses.
  16. Disease progression by infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa.
  17. HIV Type 1 transmission networks among men having sex with men and heterosexuals in Kenya.
  18. HLA-B*57 versus HLA-B*81 in HIV-1 infection: slow and steady wins the race
  19. HIV-1 clade D is associated with increased rates of CD4 decline in a Kenyan cohort.
  20. Blunted IL17/IL22 and pro-inflammatory cytokine responses in the genital tract and blood of HIV-exposed, seronegative female sex workers in Kenya.
  21. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.
  22. Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.
  23. Identifying at-risk populations in Kenya and South Africa: HIV incidence in cohorts of men who report sex with men, sex workers, and youth.
  24. Characterization of a human cervical CD4+ T cell subset coexpressing multiple markers of HIV susceptibility.
  25. Prevention of human immunodeficiency virus breastmilk transmission with copper oxide: proof-of-concept study.
  26. Human leukocyte antigen variants B*44 and B*57 are consistently favorable during two distinct phases of primary HIV-1 infection in sub-Saharan Africans with several viral subtypes.
  27. Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors.
  28. Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya AIDS vaccine initiative (KAVI), Kenya.
  29. Biological factors that may contribute to regional and racial disparities in HIV prevalence.
  30. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa.
  31. AIDS vaccines and preexposure prophylaxis: is synergy possible?
  32. Molecular characterization of HIV type 1 among HIV-infected respondents in a cohort being prepared for HIV Phase III vaccine clinical trials, Western Kenya.
  33. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
  34. Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates.
  35. Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1.
  36. CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa.
  37. Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents.
  38. Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials.
  39. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
  40. Epitope cross-reactivity frequently differs between central and effector memory HIV-specific CD8+ T cells.
  41. Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa.
  42. Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes.
  43. IL-7Ralpha expression on CD4+ T lymphocytes decreases with HIV disease progression and inversely correlates with immune activation.
  44. Standardization of cytokine flow cytometry assays.
  45. Elevation of immune activation in kenyan women is associated with alterations in immune function: implications for vaccine development.
  46. Recombination following superinfection by HIV-1.
  47. Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch.
  48. Cytokine and chemokine expression profiles in response to Mycobacterium tuberculosis stimulation are altered in HIV-infected compared to HIV-uninfected subjects with active tuberculosis.